Substrate reduction therapy in the infantile form of Tay-Sachs disease.
Substrate reduction therapy (SRT) with miglustat has been proposed for treatment of some lysosomal storage disorders. Based on the positive experience in Gaucher disease and experimental data in Tay-Sachs (TSD) and Sandhoff animal models, the authors investigated the clinical efficacy of SRT in two patients with infantile TSD. SRT could not arrest the patients' neurologic deterioration. However, a significant drug concentration in CSF as well as macrocephaly prevention were observed.
Bembi
B
B
Unità di Malattie Metaboliche, I.R.C.C.S. Burlo Garofolo, Trieste, Italy. bembi@burlo.trieste.it
Marchetti
F
F
Guerci
V I
VI
Ciana
G
G
Addobbati
R
R
Grasso
D
D
Barone
R
R
Cariati
R
R
Fernandez-Guillen
L
L
Butters
T
T
Pittis
M G
MG
D017485:1-Deoxynojirimycin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019465:Craniofacial Abnormalities / Q000517:prevention & control; D004569:Electroencephalography; D016057:Evoked Potentials, Auditory, Brain Stem; D005074:Evoked Potentials, Visual; D005260:Female; D006801:Humans; D007223:Infant; D009410:Nerve Degeneration / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D013661:Tay-Sachs Disease / Q000134:cerebrospinal fluid / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*
D017485:1-Deoxynojirimycin; C059896:miglustat